학술논문

Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study.
Document Type
Academic Journal
Source
Supportive Care in Cancer (SUPPORT CARE CANCER), Mar2023; 31(3): 1-12. (12p)
Subject
Language
English
ISSN
0941-4355